MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-26-1261

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026

A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.

Pappas Leontios, Koenig Julie L, Yeap Beow Y, Clark Jeffrey W, Klempner Samuel J, Ryan David P, Allen Jill N, Blaszkowsky Lawrence S, Giantonio Bruce J, Perez Kimberly, Schlechter Benjamin L, Wo Jennifer Y, Roberts Hannah J, Corcoran Ryan, Ting David, Meyerhardt Jeffrey A, Kantrowitz Elizabeth, Ludes Sydney D, Zecca Katharine, Drapek Lorraine C, Mehta Arnav, Hong Theodore S, Parikh Aparna R

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Immune checkpoint inhibitors (ICIs) have significantly altered the natural history of microsatellite instability high (MSI-H) colorectal cancer (mCRC). For microsatellite stable (MSS) refractory mCRC, ICIs recently demonstrated efficacy signals in patients without liver metastases. This study evaluated combined radiation therapy (RT) and ICI therapy in MSS mCRC.

PATIENTS AND

METHODS

This multi-institution, open-label, single arm Phase II study, enrolled patients with MSS mCRC previously treated with oxaliplatin, 5-fluorouracil, and irinotecan. Patients received combined RT and nivolumab/ipilimumab. The primary endpoint was the objective response rate (ORR) for unirradiated lesions. Secondary endpoints included the disease control rate (DCR) for unirradiated lesions, DCR and ORR of irradiated lesions, treatment-related adverse event (AE) rates, progression-free survival (PFS), and overall survival (OS).

RESULTS

Among 30 patients treated, the confirmed ORR was 10.0%. DCR was 33.3% and ORR was 10.0% in unirradiated lesions, and in irradiated lesions ORR was 13.3% and DCR 83.3%. In 8 patients without active liver metastases, ORR was 25.0% (95% CI, 3.2-65.1%) whereas in 22 patients with liver metastases ORR was 4.6% (95% CI, 0.1-22.8%). Median PFS was 2.4 months at median follow up of 19.8 months. The median OS of the cohort was 12.8 months (95% CI 6.8-17.9 months). Treatment was tolerable and only 10% of patients experienced grade 4 toxicity, which in all cases was lymphopenia.

CONCLUSIONS

The combination of immune-modulating, non-ablative doses of radiation therapy with ipilimumab and nivolumab has selective clinical activity in refractory MSS CRC, with responses concentrated primarily in patients without active liver metastases.

Для цитирования: Pappas Leontios, Koenig Julie L, Yeap Beow Y, Clark Jeffrey W, Klempner Samuel J, Ryan David P, Allen Jill N, Blaszkowsky Lawrence S, Giantonio Bruce J, Perez Kimberly, Schlechter Benjamin L, Wo Jennifer Y, Roberts Hannah J, Corcoran Ryan, Ting David, Meyerhardt Jeffrey A, Kantrowitz Elizabeth, Ludes Sydney D, Zecca Katharine, Drapek Lorraine C, Mehta Arnav, Hong Theodore S, Parikh Aparna R. A Phase II Study of Nivolumab and Ipilimumab with Radiation Therapy in Patients with Metastatic, Microsatellite Stable Colorectal Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. DOI: 10.1158/1078-0432.ccr-26-1261.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.